A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis

This study is a real-world clinical study of adalimumab. The project plans to enrol 30 participants and aims to evaluate the efficacy and safety of adalimumab in Chinese children with plaque psoriasis, with the primary endpoint being the proportion of participants achieving PASI 75 (PASI score reduction ≥75% from baseline) at week 16.

NCT Number	NCT07529925
Lead Sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions	Severe Plaque Psoriasis in Chinese Children
Enrollment	30 participants
Start Date	2026-05
Primary Completion	2028-04 (estimated)
Study Completion	2028-05 (estimated)
Updated on ClinicalTrials.gov	2026-04-14